Opiant Pharmaceuticals, Inc. (OPNT) News



Opiant Pharmaceuticals, Inc. (OPNT)

Today's Latest Price: $9.29 USD

0.66 (7.65%)

Updated Jan 19 3:52pm

Add OPNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

StocksNews Articles for OPNT

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest OPNT News From Around the Web

Below are the latest news stories about Opiant Pharmaceuticals Inc that investors may wish to consider to help them evaluate OPNT as an investment opportunity.

Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1 million. “We thank BARDA for their ongoing support of OPNT003, nasal nalmefene,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We believe OPNT003, nasal nalmefene, has the potential to be a best-in-class rescue...

Yahoo | December 14, 2020

Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (“Agreement”) with a syndicate of Pontifax Medison Finance (“Pontifax”), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe’s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (“FDA”) at the end of 2021.Under the Agreement, Opiant will be able ...

Yahoo | December 10, 2020

Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with over 20 years of commercial and executive experience, to Chairman of its Board of Directors, effective January 1, 2021. Mr. Collard joined the Opiant board in 2018. Gabrielle Silver, M.D., who has served as Lead Independent Director since October, 2018, will remain an independent director on the Board and continue to be Chairman of the Nominating and Governance Committee. “As we pursue our mission to deliver new medicines for addiction and overdose, I couldn’t be more excited to have Craig ...

Yahoo | December 7, 2020

Where Do Hedge Funds Stand On Opiant Pharmaceuticals, Inc. (OPNT)?

In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | November 27, 2020

Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment

Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device Reinforces Opiant’s…

GlobeNewswire | October 29, 2020

Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020

SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company…

GlobeNewswire | October 27, 2020

A Look Into Healthcare Sector Value Stocks

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.Below is a list of notable value stocks in the healthcare sector: 1. Bio-Rad Laboratories (NYSE: BIO) - P/E: 7.96 2. Jaguar Health (NASDAQ: JAGX) - P/E: 0.02 3. Opiant Pharmaceuticals (NASDAQ: OPNT) - P/E: 5.01 4. OpGen (NASDAQ: OPGN) - P/E: 2.58 5. Karuna Therapeutics (NASDAQ: KRTX) - P/E: 0.17Bio-Rad Laboratories has reported Q2 earnings per share at 1.61, which has decreased by 15.71% compared to Q1, which was 1.91. Bio-Rad Laboratories does not have a dividend yield, which investors should b...

Yahoo | September 21, 2020

Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update

SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company…

GlobeNewswire | August 6, 2020

Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets close on Thursday August 6, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday August 6, 2020. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13706176. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the ...

Yahoo | July 23, 2020

Opiant Pharmaceuticals, Inc. (OPNT): Hedge Funds Watching From Afar

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional

Yahoo Finance | November 24, 2019



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6452 seconds.